Diagnostics

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

A new collaboration between the Global Alzheimer's Platform and Alamar Biosciences aims to revolutionize diagnosis with ultra-sensitive blood tests for all.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

Swiss lab automation giant Tecan shows signs of a turnaround with robust H2 2025 orders, betting on AI to navigate a recovering life sciences market.

With a new CEO from Illumina and Exact Sciences, Quanterix signals a strategic shift from tech development to aggressive market and clinical expansion.

From firefighting robots to AI health diagnostics, Hong Kong's record delegation at CES 2026 wins big, signaling its arrival as a global tech powerhouse.

The first system pairing a one-year implantable glucose monitor with an automated insulin pump is now available, promising to transform daily life for people with diabetes.

As ENvue Medical prepares to ring the Nasdaq bell, a look at how its non-invasive tech for tube placement and pain relief is shaking up the MedTech world.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

The diagnostics firm's new offering combines sample collection with CRO and CDMO services, aiming to slash timelines and reduce regulatory risk for developers.

A breakthrough liquid biopsy shows over 80% accuracy in finding feline lymphoma, offering a non-invasive screening tool for vets and hope for cat owners.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new partnership brings revolutionary 3D genome mapping from the lab to the clinic, offering new hope for patients with hard-to-treat cancers.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Teal Health's FDA-authorized Teal Wand is now available in all 50 states, aiming to revolutionize preventive care for millions of overdue women.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?